Citi downgrades Omrix Biopharmaceuticals Inc (Nasdaq: OMRI) from Buy to Hold. Price target increased from $20 to $23.

This article: 129 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE